Adaptation of HIV-1 envelope gp120 to humoral immunity at a population level
about
Origin of the transmitted virus in HIV infection: infected cells versus cell-free virusComplex-type N-glycan recognition by potent broadly neutralizing HIV antibodiesIdentification of a cluster of HIV-1 controllers infected with low replicating virusesSimultaneously estimating evolutionary history and repeated traits phylogenetic signal: applications to viral and host phenotypic evolutionAn HIV epidemic model based on viral load dynamics: value in assessing empirical trends in HIV virulence and community viral loadA cryptic polyreactive antibody recognizes distinct clades of HIV-1 glycoprotein 120 by an identical binding mechanismIs the virulence of HIV changing? A meta-analysis of trends in prognostic markers of HIV disease progression and transmission.Partial rescue of V1V2 mutant infectivity by HIV-1 cell-cell transmission supports the domain's exceptional capacity for sequence variation.Glycosylation of the core of the HIV-1 envelope subunit protein gp120 is not required for native trimer formation or viral infectivity.Drift of the HIV-1 envelope glycoprotein gp120 toward increased neutralization resistance over the course of the epidemic: a comprehensive study using the most potent and broadly neutralizing monoclonal antibodies.Evidence for a continuous drift of the HIV-1 species towards higher resistance to neutralizing antibodies over the course of the epidemic.HIV-1 envelope glycoprotein variable loops are indispensable for envelope structural integrity and virus entry.Activity of broadly neutralizing antibodies, including PG9, PG16, and VRC01, against recently transmitted subtype B HIV-1 variants from early and late in the epidemicLonger V1V2 region with increased number of potential N-linked glycosylation sites in the HIV-1 envelope glycoprotein protects against HIV-specific neutralizing antibodies.Interaction of the gp120 V1V2 loop with a neighboring gp120 unit shields the HIV envelope trimer against cross-neutralizing antibodies.Evolution of human immunodeficiency virus type 1 in a patient with cross-reactive neutralizing activity in serum.Genotypic and functional impact of HIV-1 adaptation to its host population during the North American epidemic.Phenotypic and immunologic comparison of clade B transmitted/founder and chronic HIV-1 envelope glycoproteins.The National Heart, Lung, and Blood Institute Recipient Epidemiology and Donor Evaluation Study (REDS-III): a research program striving to improve blood donor and transfusion recipient outcomesFeline immunodeficiency virus (FIV) neutralization: a reviewLongitudinal analysis of early HIV-1-specific neutralizing activity in an elite neutralizer and in five patients who developed cross-reactive neutralizing activity.Toward a quantitative understanding of viral phylogeography.Repeated Vaccination of Cows with HIV Env gp140 during Subsequent Pregnancies Elicits and Sustains an Enduring Strong Env-Binding and Neutralising Antibody Response.Features of Recently Transmitted HIV-1 Clade C Viruses that Impact Antibody Recognition: Implications for Active and Passive ImmunizationCross-reactive broadly neutralizing antibodies: timing is everything.Diversification in the HIV-1 Envelope Hyper-variable Domains V2, V4, and V5 and Higher Probability of Transmitted/Founder Envelope Glycosylation Favor the Development of Heterologous Neutralization BreadthNoninvasive follow-up of simian immunodeficiency virus infection in wild-living nonhabituated western lowland gorillas in Cameroon.Accurate predictions of population-level changes in sequence and structural properties of HIV-1 Env using a volatility-controlled diffusion model.Evolution of an HIV glycan-dependent broadly neutralizing antibody epitope through immune escape.Significant reductions in Gag-protease-mediated HIV-1 replication capacity during the course of the epidemic in JapanComparison of viral Env proteins from acute and chronic infections with subtype C human immunodeficiency virus type 1 identifies differences in glycosylation and CCR5 utilization and suggests a new strategy for immunogen design.Genetic diversity of the highly variable V1 region interferes with Human Immunodeficiency Virus type 1 envelope functionalityHIV-1 envelope glycoprotein signatures that correlate with the development of cross-reactive neutralizing activity.The cannabinoid CB₂ receptor agonist AM1241 enhances neurogenesis in GFAP/Gp120 transgenic mice displaying deficits in neurogenesis.Neutralizing antibodies and control of HIV: moves and countermoves.A Relaxed Directional Random Walk Model for Phylogenetic Trait Evolution.Human immunodeficiency virus type 1 biological variation and coreceptor use: from concept to clinical significance.The V1 region of gp120 is preferentially selected during SIV/HIV transmission and is indispensable for envelope function and virus infection.Env-Specific Antibodies in Chronic Infection versus in Vaccination.Sequential evolution and escape from neutralization of simian immunodeficiency virus SIVsmE660 clones in rhesus macaques.
P2860
Q27021279-5E415F2B-8D9E-44C9-9A46-CE39B4649B18Q27674878-250BDC32-43ED-4ED2-8032-17C53302DEBEQ28534737-EA0ABE3C-267D-49D4-837D-52DAD5AA97C9Q28652426-3F1A7C2D-A066-4A47-BBD0-8422B5A8331EQ30363755-510B283B-7627-46D4-8648-FAF679A00473Q33793007-F09F1581-4B64-4A41-95A6-B534845AB88EQ34029430-62D70ABB-5C41-46C7-A909-4A33CF31EBFCQ34309493-73FFF1EB-B3AD-449E-AB11-FC0ED2E727D9Q34555891-C3A34998-1624-4905-AEEC-0418811B5D7DQ34594036-130312AB-DE65-407B-A929-797767E44C05Q34819651-E68006B9-7BF2-442E-9962-BB4D923845D7Q34924647-A62DD326-9B9A-4434-A976-E04A23DAB9B3Q35077704-C8DF3BBE-85DE-4F4E-9D13-B83018AE65DEQ35077797-C8BDDB39-D8E3-4C2F-986C-81FE51DEB902Q35102328-D0D9423A-66DD-4E11-B6F2-C41D6EDEE2C9Q35140461-6FC90622-4E64-4B1D-89E6-124387824E17Q35156765-86D44C0B-3A56-4D9A-ABF8-37F9C6D15982Q35192915-15D03270-47FA-439B-9C10-2740B5B28D16Q35251300-25FBE4F2-6191-4E48-803B-E8685951F27BQ35491705-5123781F-2A32-4431-8CC3-A46CD1733424Q35826458-0C029501-DF6B-44ED-8B49-2F502CD26CE4Q35854178-B7481F6F-620A-4E36-89B6-BCD56484C48BQ36051764-1327BF32-8CBB-42A1-951D-3519D8CADB4CQ36081789-FE341259-A479-4E34-B4EA-A456013C31DDQ36105782-A81BA402-5948-4343-9BA1-8F59D15FF030Q36194234-A23581FC-BF3F-48CC-8E5F-BA361648E5C2Q36246353-F6AD9FD1-18BB-4690-9DA8-85A3D7361490Q36337888-02EFF3AC-70FA-419A-B63E-DD6661FD2A53Q36388754-88596382-CC80-4D31-9525-C6D6FFBEE63AQ36559805-2D922050-9C2A-472D-9D1A-6F848A450865Q36978861-EDFA2DA8-276F-4D82-87B9-840377728DEAQ37305864-950F4780-5B06-41CA-807E-39351365E12EQ37360774-0528BE09-201D-4F7B-8499-BBAFFD872F35Q37522883-2DB992A0-1FF8-4C8E-A4E9-A029B8217CD8Q37971867-BB2A9430-83A9-482F-8C3B-F74E65864CE8Q39231129-C7156DD7-4D2A-4DCF-A324-FED291887A92Q39471859-F105DA95-603C-4112-8ED4-C66121ED22B4Q40697873-E427BD66-5507-45FE-B5DE-30E40424356AQ41475637-7F94337B-10E3-4030-9747-EA84BCB5AB28Q41876895-1C54C2F8-A962-4206-9F2A-D69C360B31F9
P2860
Adaptation of HIV-1 envelope gp120 to humoral immunity at a population level
description
article
@en
im August 2010 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована в серпні 2010
@uk
name
Adaptation of HIV-1 envelope gp120 to humoral immunity at a population level
@en
Adaptation of HIV-1 envelope gp120 to humoral immunity at a population level
@nl
type
label
Adaptation of HIV-1 envelope gp120 to humoral immunity at a population level
@en
Adaptation of HIV-1 envelope gp120 to humoral immunity at a population level
@nl
prefLabel
Adaptation of HIV-1 envelope gp120 to humoral immunity at a population level
@en
Adaptation of HIV-1 envelope gp120 to humoral immunity at a population level
@nl
P2093
P356
P1433
P1476
Adaptation of HIV-1 envelope gp120 to humoral immunity at a population level
@en
P2093
Brigitte D M Boeser-Nunnink
Hanneke Schuitemaker
Jan M Prins
Marlous L Grijsen
Zelda Euler
P2888
P304
P356
10.1038/NM.2203
P407
P577
2010-08-29T00:00:00Z